MedComm-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2203542, encodeId=55d9220354217, content=审稿速度:12.0 经验分享：2023-07-01投稿，2023.11-30大修，2024.02.01修回，目前2024.05.08还在审稿中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed4d1295453, createdName=1111111111111111111111, createdTime=Wed May 08 22:55:36 CST 2024, time=2024-05-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2200373, encodeId=79e422003e3dd, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：遗传学 经验分享：期刊目前还属于ESCI，非SCI。审稿速度慢，审稿人和编辑都很负责任。文章接受后等online花了将近3个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c6495142178, createdName=smmm, createdTime=Thu Apr 25 16:52:34 CST 2024, time=2024-04-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2189981, encodeId=96e221899819a, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤药理 经验分享：23年6月2投，今天2024年2月28接收，来来回回三轮revise，只能说对文章的要求真的高，23年IF肯定＞10了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c25102995, createdName=145fac5am20暂无昵称, createdTime=Wed Feb 28 22:00:43 CST 2024, time=2024-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2175362, encodeId=981121e536202, content=修回之后under review之后变成pending recommendation，但是后来又under review了。这是有审稿人不满意吗，还是审稿人不够啊…而且也太慢太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83epxYEMeM41N9n76P8Xn6Fy2L47YtWpP4fVuUZMZSAYnf6zW01CJWE2u7iaMTUicChIOKdsvNibjS3q7w/0, createdBy=f1fd2219511, createdName=ms5078924656919134, createdTime=Sun Dec 17 03:09:26 CST 2023, time=2023-12-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2212350, encodeId=3ebb22123503e, content=偏重的研究方向：基础研究;综述 经验分享：initial check需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Sat Jun 29 16:50:37 CST 2024, time=2024-06-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2209054, encodeId=206e220905457, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：基础研究 经验分享：从顶刊一直偷下来，到了medcomm一审接近三个月，小修1个多月，最后接收。有幸选为封面，最近也审了几篇medcomm的稿子，怎么说呢?大部分质量还行，实时影响因子也超10分了，月底公布的23年IF应该也是大于10的，唯一缺点就是还不算是sci。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202402/d5b9725163204491b176bcaa0ee488be.jpg, createdBy=d4b72283806, createdName=red cell, createdTime=Sun Jun 09 08:44:04 CST 2024, time=2024-06-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2211875, encodeId=03a222118e5eb, content=审稿速度:3.0 经验分享：Under review是送审了还是还在编辑手里?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Thu Jun 27 08:47:56 CST 2024, time=2024-06-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210710, encodeId=a3b82210e10db, content=看来今年也进不了sci了，也不能拿来毕业，导师也不能拿来评职称，甚至版面费都不能报销，esci就是一个纯纯的骗局, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Jun 19 20:40:31 CST 2024, time=2024-06-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2210802, encodeId=c2272210802d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;综合期刊;遗传学 经验分享：2023年度影响因子为10.7分，不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:59:06 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊)]

2024-05-27 shuchao 来自湖南省

审稿速度:3.0
经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？

30 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2203542, encodeId=55d9220354217, content=审稿速度:12.0 经验分享：2023-07-01投稿，2023.11-30大修，2024.02.01修回，目前2024.05.08还在审稿中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed4d1295453, createdName=1111111111111111111111, createdTime=Wed May 08 22:55:36 CST 2024, time=2024-05-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2200373, encodeId=79e422003e3dd, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：遗传学 经验分享：期刊目前还属于ESCI，非SCI。审稿速度慢，审稿人和编辑都很负责任。文章接受后等online花了将近3个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c6495142178, createdName=smmm, createdTime=Thu Apr 25 16:52:34 CST 2024, time=2024-04-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2189981, encodeId=96e221899819a, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤药理 经验分享：23年6月2投，今天2024年2月28接收，来来回回三轮revise，只能说对文章的要求真的高，23年IF肯定＞10了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c25102995, createdName=145fac5am20暂无昵称, createdTime=Wed Feb 28 22:00:43 CST 2024, time=2024-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2175362, encodeId=981121e536202, content=修回之后under review之后变成pending recommendation，但是后来又under review了。这是有审稿人不满意吗，还是审稿人不够啊…而且也太慢太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83epxYEMeM41N9n76P8Xn6Fy2L47YtWpP4fVuUZMZSAYnf6zW01CJWE2u7iaMTUicChIOKdsvNibjS3q7w/0, createdBy=f1fd2219511, createdName=ms5078924656919134, createdTime=Sun Dec 17 03:09:26 CST 2023, time=2023-12-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2212350, encodeId=3ebb22123503e, content=偏重的研究方向：基础研究;综述 经验分享：initial check需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Sat Jun 29 16:50:37 CST 2024, time=2024-06-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2209054, encodeId=206e220905457, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：基础研究 经验分享：从顶刊一直偷下来，到了medcomm一审接近三个月，小修1个多月，最后接收。有幸选为封面，最近也审了几篇medcomm的稿子，怎么说呢?大部分质量还行，实时影响因子也超10分了，月底公布的23年IF应该也是大于10的，唯一缺点就是还不算是sci。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202402/d5b9725163204491b176bcaa0ee488be.jpg, createdBy=d4b72283806, createdName=red cell, createdTime=Sun Jun 09 08:44:04 CST 2024, time=2024-06-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2211875, encodeId=03a222118e5eb, content=审稿速度:3.0 经验分享：Under review是送审了还是还在编辑手里?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Thu Jun 27 08:47:56 CST 2024, time=2024-06-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210710, encodeId=a3b82210e10db, content=看来今年也进不了sci了，也不能拿来毕业，导师也不能拿来评职称，甚至版面费都不能报销，esci就是一个纯纯的骗局, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Jun 19 20:40:31 CST 2024, time=2024-06-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2210802, encodeId=c2272210802d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;综合期刊;遗传学 经验分享：2023年度影响因子为10.7分，不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:59:06 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊)]

2024-05-08 1111111111111111111111 来自上海

审稿速度:12.0
经验分享：2023-07-01投稿，2023.11-30大修，2024.02.01修回，目前2024.05.08还在审稿中。

37 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2203542, encodeId=55d9220354217, content=审稿速度:12.0 经验分享：2023-07-01投稿，2023.11-30大修，2024.02.01修回，目前2024.05.08还在审稿中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed4d1295453, createdName=1111111111111111111111, createdTime=Wed May 08 22:55:36 CST 2024, time=2024-05-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2200373, encodeId=79e422003e3dd, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：遗传学 经验分享：期刊目前还属于ESCI，非SCI。审稿速度慢，审稿人和编辑都很负责任。文章接受后等online花了将近3个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c6495142178, createdName=smmm, createdTime=Thu Apr 25 16:52:34 CST 2024, time=2024-04-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2189981, encodeId=96e221899819a, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤药理 经验分享：23年6月2投，今天2024年2月28接收，来来回回三轮revise，只能说对文章的要求真的高，23年IF肯定＞10了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c25102995, createdName=145fac5am20暂无昵称, createdTime=Wed Feb 28 22:00:43 CST 2024, time=2024-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2175362, encodeId=981121e536202, content=修回之后under review之后变成pending recommendation，但是后来又under review了。这是有审稿人不满意吗，还是审稿人不够啊…而且也太慢太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83epxYEMeM41N9n76P8Xn6Fy2L47YtWpP4fVuUZMZSAYnf6zW01CJWE2u7iaMTUicChIOKdsvNibjS3q7w/0, createdBy=f1fd2219511, createdName=ms5078924656919134, createdTime=Sun Dec 17 03:09:26 CST 2023, time=2023-12-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2212350, encodeId=3ebb22123503e, content=偏重的研究方向：基础研究;综述 经验分享：initial check需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Sat Jun 29 16:50:37 CST 2024, time=2024-06-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2209054, encodeId=206e220905457, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：基础研究 经验分享：从顶刊一直偷下来，到了medcomm一审接近三个月，小修1个多月，最后接收。有幸选为封面，最近也审了几篇medcomm的稿子，怎么说呢?大部分质量还行，实时影响因子也超10分了，月底公布的23年IF应该也是大于10的，唯一缺点就是还不算是sci。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202402/d5b9725163204491b176bcaa0ee488be.jpg, createdBy=d4b72283806, createdName=red cell, createdTime=Sun Jun 09 08:44:04 CST 2024, time=2024-06-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2211875, encodeId=03a222118e5eb, content=审稿速度:3.0 经验分享：Under review是送审了还是还在编辑手里?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Thu Jun 27 08:47:56 CST 2024, time=2024-06-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210710, encodeId=a3b82210e10db, content=看来今年也进不了sci了，也不能拿来毕业，导师也不能拿来评职称，甚至版面费都不能报销，esci就是一个纯纯的骗局, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Jun 19 20:40:31 CST 2024, time=2024-06-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2210802, encodeId=c2272210802d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;综合期刊;遗传学 经验分享：2023年度影响因子为10.7分，不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:59:06 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊)]

2024-04-25 smmm 来自浙江省

审稿速度:6.0 | 投稿命中率:25.0
偏重的研究方向：遗传学
经验分享：期刊目前还属于ESCI，非SCI。审稿速度慢，审稿人和编辑都很负责任。文章接受后等online花了将近3个月时间。

36 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2203542, encodeId=55d9220354217, content=审稿速度:12.0 经验分享：2023-07-01投稿，2023.11-30大修，2024.02.01修回，目前2024.05.08还在审稿中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed4d1295453, createdName=1111111111111111111111, createdTime=Wed May 08 22:55:36 CST 2024, time=2024-05-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2200373, encodeId=79e422003e3dd, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：遗传学 经验分享：期刊目前还属于ESCI，非SCI。审稿速度慢，审稿人和编辑都很负责任。文章接受后等online花了将近3个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c6495142178, createdName=smmm, createdTime=Thu Apr 25 16:52:34 CST 2024, time=2024-04-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2189981, encodeId=96e221899819a, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤药理 经验分享：23年6月2投，今天2024年2月28接收，来来回回三轮revise，只能说对文章的要求真的高，23年IF肯定＞10了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c25102995, createdName=145fac5am20暂无昵称, createdTime=Wed Feb 28 22:00:43 CST 2024, time=2024-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2175362, encodeId=981121e536202, content=修回之后under review之后变成pending recommendation，但是后来又under review了。这是有审稿人不满意吗，还是审稿人不够啊…而且也太慢太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83epxYEMeM41N9n76P8Xn6Fy2L47YtWpP4fVuUZMZSAYnf6zW01CJWE2u7iaMTUicChIOKdsvNibjS3q7w/0, createdBy=f1fd2219511, createdName=ms5078924656919134, createdTime=Sun Dec 17 03:09:26 CST 2023, time=2023-12-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2212350, encodeId=3ebb22123503e, content=偏重的研究方向：基础研究;综述 经验分享：initial check需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Sat Jun 29 16:50:37 CST 2024, time=2024-06-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2209054, encodeId=206e220905457, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：基础研究 经验分享：从顶刊一直偷下来，到了medcomm一审接近三个月，小修1个多月，最后接收。有幸选为封面，最近也审了几篇medcomm的稿子，怎么说呢?大部分质量还行，实时影响因子也超10分了，月底公布的23年IF应该也是大于10的，唯一缺点就是还不算是sci。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202402/d5b9725163204491b176bcaa0ee488be.jpg, createdBy=d4b72283806, createdName=red cell, createdTime=Sun Jun 09 08:44:04 CST 2024, time=2024-06-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2211875, encodeId=03a222118e5eb, content=审稿速度:3.0 经验分享：Under review是送审了还是还在编辑手里?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Thu Jun 27 08:47:56 CST 2024, time=2024-06-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210710, encodeId=a3b82210e10db, content=看来今年也进不了sci了，也不能拿来毕业，导师也不能拿来评职称，甚至版面费都不能报销，esci就是一个纯纯的骗局, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Jun 19 20:40:31 CST 2024, time=2024-06-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2210802, encodeId=c2272210802d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;综合期刊;遗传学 经验分享：2023年度影响因子为10.7分，不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:59:06 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊)]

2024-02-28 145fac5am20暂无昵称来自上海

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤药理
经验分享：23年6月2投，今天2024年2月28接收，来来回回三轮revise，只能说对文章的要求真的高，23年IF肯定＞10了！

53 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2203542, encodeId=55d9220354217, content=审稿速度:12.0 经验分享：2023-07-01投稿，2023.11-30大修，2024.02.01修回，目前2024.05.08还在审稿中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed4d1295453, createdName=1111111111111111111111, createdTime=Wed May 08 22:55:36 CST 2024, time=2024-05-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2200373, encodeId=79e422003e3dd, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：遗传学 经验分享：期刊目前还属于ESCI，非SCI。审稿速度慢，审稿人和编辑都很负责任。文章接受后等online花了将近3个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c6495142178, createdName=smmm, createdTime=Thu Apr 25 16:52:34 CST 2024, time=2024-04-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2189981, encodeId=96e221899819a, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤药理 经验分享：23年6月2投，今天2024年2月28接收，来来回回三轮revise，只能说对文章的要求真的高，23年IF肯定＞10了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c25102995, createdName=145fac5am20暂无昵称, createdTime=Wed Feb 28 22:00:43 CST 2024, time=2024-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2175362, encodeId=981121e536202, content=修回之后under review之后变成pending recommendation，但是后来又under review了。这是有审稿人不满意吗，还是审稿人不够啊…而且也太慢太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83epxYEMeM41N9n76P8Xn6Fy2L47YtWpP4fVuUZMZSAYnf6zW01CJWE2u7iaMTUicChIOKdsvNibjS3q7w/0, createdBy=f1fd2219511, createdName=ms5078924656919134, createdTime=Sun Dec 17 03:09:26 CST 2023, time=2023-12-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2212350, encodeId=3ebb22123503e, content=偏重的研究方向：基础研究;综述 经验分享：initial check需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Sat Jun 29 16:50:37 CST 2024, time=2024-06-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2209054, encodeId=206e220905457, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：基础研究 经验分享：从顶刊一直偷下来，到了medcomm一审接近三个月，小修1个多月，最后接收。有幸选为封面，最近也审了几篇medcomm的稿子，怎么说呢?大部分质量还行，实时影响因子也超10分了，月底公布的23年IF应该也是大于10的，唯一缺点就是还不算是sci。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202402/d5b9725163204491b176bcaa0ee488be.jpg, createdBy=d4b72283806, createdName=red cell, createdTime=Sun Jun 09 08:44:04 CST 2024, time=2024-06-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2211875, encodeId=03a222118e5eb, content=审稿速度:3.0 经验分享：Under review是送审了还是还在编辑手里?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Thu Jun 27 08:47:56 CST 2024, time=2024-06-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210710, encodeId=a3b82210e10db, content=看来今年也进不了sci了，也不能拿来毕业，导师也不能拿来评职称，甚至版面费都不能报销，esci就是一个纯纯的骗局, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Jun 19 20:40:31 CST 2024, time=2024-06-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2210802, encodeId=c2272210802d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;综合期刊;遗传学 经验分享：2023年度影响因子为10.7分，不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:59:06 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊)]

2023-12-17 ms5078924656919134 来自上海

修回之后under review之后变成pending recommendation，但是后来又under review了。这是有审稿人不满意吗，还是审稿人不够啊…而且也太慢太慢了

71 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2203542, encodeId=55d9220354217, content=审稿速度:12.0 经验分享：2023-07-01投稿，2023.11-30大修，2024.02.01修回，目前2024.05.08还在审稿中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed4d1295453, createdName=1111111111111111111111, createdTime=Wed May 08 22:55:36 CST 2024, time=2024-05-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2200373, encodeId=79e422003e3dd, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：遗传学 经验分享：期刊目前还属于ESCI，非SCI。审稿速度慢，审稿人和编辑都很负责任。文章接受后等online花了将近3个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c6495142178, createdName=smmm, createdTime=Thu Apr 25 16:52:34 CST 2024, time=2024-04-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2189981, encodeId=96e221899819a, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤药理 经验分享：23年6月2投，今天2024年2月28接收，来来回回三轮revise，只能说对文章的要求真的高，23年IF肯定＞10了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c25102995, createdName=145fac5am20暂无昵称, createdTime=Wed Feb 28 22:00:43 CST 2024, time=2024-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2175362, encodeId=981121e536202, content=修回之后under review之后变成pending recommendation，但是后来又under review了。这是有审稿人不满意吗，还是审稿人不够啊…而且也太慢太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83epxYEMeM41N9n76P8Xn6Fy2L47YtWpP4fVuUZMZSAYnf6zW01CJWE2u7iaMTUicChIOKdsvNibjS3q7w/0, createdBy=f1fd2219511, createdName=ms5078924656919134, createdTime=Sun Dec 17 03:09:26 CST 2023, time=2023-12-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2212350, encodeId=3ebb22123503e, content=偏重的研究方向：基础研究;综述 经验分享：initial check需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Sat Jun 29 16:50:37 CST 2024, time=2024-06-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2209054, encodeId=206e220905457, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：基础研究 经验分享：从顶刊一直偷下来，到了medcomm一审接近三个月，小修1个多月，最后接收。有幸选为封面，最近也审了几篇medcomm的稿子，怎么说呢?大部分质量还行，实时影响因子也超10分了，月底公布的23年IF应该也是大于10的，唯一缺点就是还不算是sci。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202402/d5b9725163204491b176bcaa0ee488be.jpg, createdBy=d4b72283806, createdName=red cell, createdTime=Sun Jun 09 08:44:04 CST 2024, time=2024-06-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2211875, encodeId=03a222118e5eb, content=审稿速度:3.0 经验分享：Under review是送审了还是还在编辑手里?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Thu Jun 27 08:47:56 CST 2024, time=2024-06-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210710, encodeId=a3b82210e10db, content=看来今年也进不了sci了，也不能拿来毕业，导师也不能拿来评职称，甚至版面费都不能报销，esci就是一个纯纯的骗局, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Jun 19 20:40:31 CST 2024, time=2024-06-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2210802, encodeId=c2272210802d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;综合期刊;遗传学 经验分享：2023年度影响因子为10.7分，不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:59:06 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊)]

2024-06-29 ms6000001702952186 来自河南省

偏重的研究方向：基础研究;综述
经验分享：initial check需要多久？

24 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2203542, encodeId=55d9220354217, content=审稿速度:12.0 经验分享：2023-07-01投稿，2023.11-30大修，2024.02.01修回，目前2024.05.08还在审稿中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed4d1295453, createdName=1111111111111111111111, createdTime=Wed May 08 22:55:36 CST 2024, time=2024-05-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2200373, encodeId=79e422003e3dd, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：遗传学 经验分享：期刊目前还属于ESCI，非SCI。审稿速度慢，审稿人和编辑都很负责任。文章接受后等online花了将近3个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c6495142178, createdName=smmm, createdTime=Thu Apr 25 16:52:34 CST 2024, time=2024-04-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2189981, encodeId=96e221899819a, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤药理 经验分享：23年6月2投，今天2024年2月28接收，来来回回三轮revise，只能说对文章的要求真的高，23年IF肯定＞10了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c25102995, createdName=145fac5am20暂无昵称, createdTime=Wed Feb 28 22:00:43 CST 2024, time=2024-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2175362, encodeId=981121e536202, content=修回之后under review之后变成pending recommendation，但是后来又under review了。这是有审稿人不满意吗，还是审稿人不够啊…而且也太慢太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83epxYEMeM41N9n76P8Xn6Fy2L47YtWpP4fVuUZMZSAYnf6zW01CJWE2u7iaMTUicChIOKdsvNibjS3q7w/0, createdBy=f1fd2219511, createdName=ms5078924656919134, createdTime=Sun Dec 17 03:09:26 CST 2023, time=2023-12-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2212350, encodeId=3ebb22123503e, content=偏重的研究方向：基础研究;综述 经验分享：initial check需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Sat Jun 29 16:50:37 CST 2024, time=2024-06-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2209054, encodeId=206e220905457, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：基础研究 经验分享：从顶刊一直偷下来，到了medcomm一审接近三个月，小修1个多月，最后接收。有幸选为封面，最近也审了几篇medcomm的稿子，怎么说呢?大部分质量还行，实时影响因子也超10分了，月底公布的23年IF应该也是大于10的，唯一缺点就是还不算是sci。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202402/d5b9725163204491b176bcaa0ee488be.jpg, createdBy=d4b72283806, createdName=red cell, createdTime=Sun Jun 09 08:44:04 CST 2024, time=2024-06-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2211875, encodeId=03a222118e5eb, content=审稿速度:3.0 经验分享：Under review是送审了还是还在编辑手里?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Thu Jun 27 08:47:56 CST 2024, time=2024-06-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210710, encodeId=a3b82210e10db, content=看来今年也进不了sci了，也不能拿来毕业，导师也不能拿来评职称，甚至版面费都不能报销，esci就是一个纯纯的骗局, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Jun 19 20:40:31 CST 2024, time=2024-06-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2210802, encodeId=c2272210802d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;综合期刊;遗传学 经验分享：2023年度影响因子为10.7分，不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:59:06 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊)]

2024-06-09 red cell 来自陕西省

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：基础研究
经验分享：从顶刊一直偷下来，到了medcomm一审接近三个月，小修1个多月，最后接收。有幸选为封面，最近也审了几篇medcomm的稿子，怎么说呢?大部分质量还行，实时影响因子也超10分了，月底公布的23年IF应该也是大于10的，唯一缺点就是还不算是sci。

33 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2203542, encodeId=55d9220354217, content=审稿速度:12.0 经验分享：2023-07-01投稿，2023.11-30大修，2024.02.01修回，目前2024.05.08还在审稿中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed4d1295453, createdName=1111111111111111111111, createdTime=Wed May 08 22:55:36 CST 2024, time=2024-05-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2200373, encodeId=79e422003e3dd, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：遗传学 经验分享：期刊目前还属于ESCI，非SCI。审稿速度慢，审稿人和编辑都很负责任。文章接受后等online花了将近3个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c6495142178, createdName=smmm, createdTime=Thu Apr 25 16:52:34 CST 2024, time=2024-04-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2189981, encodeId=96e221899819a, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤药理 经验分享：23年6月2投，今天2024年2月28接收，来来回回三轮revise，只能说对文章的要求真的高，23年IF肯定＞10了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c25102995, createdName=145fac5am20暂无昵称, createdTime=Wed Feb 28 22:00:43 CST 2024, time=2024-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2175362, encodeId=981121e536202, content=修回之后under review之后变成pending recommendation，但是后来又under review了。这是有审稿人不满意吗，还是审稿人不够啊…而且也太慢太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83epxYEMeM41N9n76P8Xn6Fy2L47YtWpP4fVuUZMZSAYnf6zW01CJWE2u7iaMTUicChIOKdsvNibjS3q7w/0, createdBy=f1fd2219511, createdName=ms5078924656919134, createdTime=Sun Dec 17 03:09:26 CST 2023, time=2023-12-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2212350, encodeId=3ebb22123503e, content=偏重的研究方向：基础研究;综述 经验分享：initial check需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Sat Jun 29 16:50:37 CST 2024, time=2024-06-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2209054, encodeId=206e220905457, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：基础研究 经验分享：从顶刊一直偷下来，到了medcomm一审接近三个月，小修1个多月，最后接收。有幸选为封面，最近也审了几篇medcomm的稿子，怎么说呢?大部分质量还行，实时影响因子也超10分了，月底公布的23年IF应该也是大于10的，唯一缺点就是还不算是sci。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202402/d5b9725163204491b176bcaa0ee488be.jpg, createdBy=d4b72283806, createdName=red cell, createdTime=Sun Jun 09 08:44:04 CST 2024, time=2024-06-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2211875, encodeId=03a222118e5eb, content=审稿速度:3.0 经验分享：Under review是送审了还是还在编辑手里?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Thu Jun 27 08:47:56 CST 2024, time=2024-06-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210710, encodeId=a3b82210e10db, content=看来今年也进不了sci了，也不能拿来毕业，导师也不能拿来评职称，甚至版面费都不能报销，esci就是一个纯纯的骗局, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Jun 19 20:40:31 CST 2024, time=2024-06-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2210802, encodeId=c2272210802d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;综合期刊;遗传学 经验分享：2023年度影响因子为10.7分，不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:59:06 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊)]

2024-06-27 snowboy 来自云南省

审稿速度:3.0
经验分享：Under review是送审了还是还在编辑手里?

21 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2203542, encodeId=55d9220354217, content=审稿速度:12.0 经验分享：2023-07-01投稿，2023.11-30大修，2024.02.01修回，目前2024.05.08还在审稿中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed4d1295453, createdName=1111111111111111111111, createdTime=Wed May 08 22:55:36 CST 2024, time=2024-05-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2200373, encodeId=79e422003e3dd, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：遗传学 经验分享：期刊目前还属于ESCI，非SCI。审稿速度慢，审稿人和编辑都很负责任。文章接受后等online花了将近3个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c6495142178, createdName=smmm, createdTime=Thu Apr 25 16:52:34 CST 2024, time=2024-04-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2189981, encodeId=96e221899819a, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤药理 经验分享：23年6月2投，今天2024年2月28接收，来来回回三轮revise，只能说对文章的要求真的高，23年IF肯定＞10了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c25102995, createdName=145fac5am20暂无昵称, createdTime=Wed Feb 28 22:00:43 CST 2024, time=2024-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2175362, encodeId=981121e536202, content=修回之后under review之后变成pending recommendation，但是后来又under review了。这是有审稿人不满意吗，还是审稿人不够啊…而且也太慢太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83epxYEMeM41N9n76P8Xn6Fy2L47YtWpP4fVuUZMZSAYnf6zW01CJWE2u7iaMTUicChIOKdsvNibjS3q7w/0, createdBy=f1fd2219511, createdName=ms5078924656919134, createdTime=Sun Dec 17 03:09:26 CST 2023, time=2023-12-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2212350, encodeId=3ebb22123503e, content=偏重的研究方向：基础研究;综述 经验分享：initial check需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Sat Jun 29 16:50:37 CST 2024, time=2024-06-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2209054, encodeId=206e220905457, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：基础研究 经验分享：从顶刊一直偷下来，到了medcomm一审接近三个月，小修1个多月，最后接收。有幸选为封面，最近也审了几篇medcomm的稿子，怎么说呢?大部分质量还行，实时影响因子也超10分了，月底公布的23年IF应该也是大于10的，唯一缺点就是还不算是sci。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202402/d5b9725163204491b176bcaa0ee488be.jpg, createdBy=d4b72283806, createdName=red cell, createdTime=Sun Jun 09 08:44:04 CST 2024, time=2024-06-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2211875, encodeId=03a222118e5eb, content=审稿速度:3.0 经验分享：Under review是送审了还是还在编辑手里?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Thu Jun 27 08:47:56 CST 2024, time=2024-06-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210710, encodeId=a3b82210e10db, content=看来今年也进不了sci了，也不能拿来毕业，导师也不能拿来评职称，甚至版面费都不能报销，esci就是一个纯纯的骗局, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Jun 19 20:40:31 CST 2024, time=2024-06-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2210802, encodeId=c2272210802d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;综合期刊;遗传学 经验分享：2023年度影响因子为10.7分，不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:59:06 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊)]

2024-06-19 148cbeecm22暂无昵称来自湖北省

看来今年也进不了sci了，也不能拿来毕业，导师也不能拿来评职称，甚至版面费都不能报销，esci就是一个纯纯的骗局

58 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2203542, encodeId=55d9220354217, content=审稿速度:12.0 经验分享：2023-07-01投稿，2023.11-30大修，2024.02.01修回，目前2024.05.08还在审稿中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed4d1295453, createdName=1111111111111111111111, createdTime=Wed May 08 22:55:36 CST 2024, time=2024-05-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2200373, encodeId=79e422003e3dd, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：遗传学 经验分享：期刊目前还属于ESCI，非SCI。审稿速度慢，审稿人和编辑都很负责任。文章接受后等online花了将近3个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c6495142178, createdName=smmm, createdTime=Thu Apr 25 16:52:34 CST 2024, time=2024-04-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2189981, encodeId=96e221899819a, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤药理 经验分享：23年6月2投，今天2024年2月28接收，来来回回三轮revise，只能说对文章的要求真的高，23年IF肯定＞10了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c25102995, createdName=145fac5am20暂无昵称, createdTime=Wed Feb 28 22:00:43 CST 2024, time=2024-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2175362, encodeId=981121e536202, content=修回之后under review之后变成pending recommendation，但是后来又under review了。这是有审稿人不满意吗，还是审稿人不够啊…而且也太慢太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83epxYEMeM41N9n76P8Xn6Fy2L47YtWpP4fVuUZMZSAYnf6zW01CJWE2u7iaMTUicChIOKdsvNibjS3q7w/0, createdBy=f1fd2219511, createdName=ms5078924656919134, createdTime=Sun Dec 17 03:09:26 CST 2023, time=2023-12-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2212350, encodeId=3ebb22123503e, content=偏重的研究方向：基础研究;综述 经验分享：initial check需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Sat Jun 29 16:50:37 CST 2024, time=2024-06-29, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2209054, encodeId=206e220905457, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：基础研究 经验分享：从顶刊一直偷下来，到了medcomm一审接近三个月，小修1个多月，最后接收。有幸选为封面，最近也审了几篇medcomm的稿子，怎么说呢?大部分质量还行，实时影响因子也超10分了，月底公布的23年IF应该也是大于10的，唯一缺点就是还不算是sci。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202402/d5b9725163204491b176bcaa0ee488be.jpg, createdBy=d4b72283806, createdName=red cell, createdTime=Sun Jun 09 08:44:04 CST 2024, time=2024-06-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2211875, encodeId=03a222118e5eb, content=审稿速度:3.0 经验分享：Under review是送审了还是还在编辑手里?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Thu Jun 27 08:47:56 CST 2024, time=2024-06-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210710, encodeId=a3b82210e10db, content=看来今年也进不了sci了，也不能拿来毕业，导师也不能拿来评职称，甚至版面费都不能报销，esci就是一个纯纯的骗局, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Jun 19 20:40:31 CST 2024, time=2024-06-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2210802, encodeId=c2272210802d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;综合期刊;遗传学 经验分享：2023年度影响因子为10.7分，不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 20 13:59:06 CST 2024, time=2024-06-20, status=1, ipAttribution=伊利诺伊)]

2024-06-20 侠胆医心来自伊利诺伊

审稿速度:3.0 | 投稿命中率:25.0
偏重的研究方向：转化医学;综合期刊;遗传学
经验分享：2023年度影响因子为10.7分，不错

50 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务